Genter Capital股利收益主动型ETF GEND 深 沪
等待开盘 07-02 09:30:00 美东时间
12.7013
0.000
0.00%
华盛通- 最 高0.00
- 今 开12.7013
- 成交量 159股
- 最 低 0.00
- 昨 收 12.7013
- 总市值 482.65万
- 52周最高 13.6562
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 10.3901
- 委 比 -66.67%
- 总股本 38.00万
- 历史最高 13.6562
- 量 比 0.38
- 振 幅 0.00%
- 历史最低 8.7266
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多As Supreme Court's term nears its end, three major Trump rulings due
As Supreme Court's term nears its end, three major Trump rulings due Justices consider Trump's move to fire Fed and FTC officials Ruling due on Trump order limiting birthright citizenship Decisions loom on mail-in ballots, campaign finance limits Legality of transgender athletes crackdown to be deci
06-28 18:00
BRIEF-Legend Biotech Corporation Announces Pricing Of Public Offering
BRIEF-Legend Biotech Corporation Announces Pricing Of Public Offering June 17 (Reuters) - Legend Biotech Corp LEGN.O : LEGEND BIOTECH CORPORATION ANNOUNCES PRICING OF PUBLIC OFFERING LEGEND BIOTECH - PRICES 7.7 MILLION ADS PUBLIC OFFERING AT $29.35 PER ADS LEGEND BIOTECH - GROSS PROCEEDS FROM OFFERI
06-18 09:24
enGene Holdings GAAP EPS of $0.43
enGene Holdings press release (ENGN): Q2 GAAP EPS of $0.43. As of April 30, 2026, cash, cash equivalents and marketable securities were $285.2 million providing significant operational flexibility. To...
06-15 22:12
BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501
BRIEF-Legend Biotech Announces Promising Preliminary Clinical Data For LB2501 June 2 (Reuters) - Legend Biotech Corp LEGN.O : LEGEND BIOTECH: PROMISING INITIAL PHASE 1 CLINICAL DATA FOR LB2501 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA LEGEND BIOTECH: 100% ORR (6/6) OBSERVED IN
06-02 21:30
Why Is enGene Therapeutics Stock Falling Friday?
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
05-08 23:34
Dow Dips 350 Points; US Foods Posts Downbeat Earnings
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains while Entrada, Fastly, and enGene Therapeutics decline. Euro zone and Asian markets mixed.
05-08 01:39
enGene Holdings To Change Its Corporate Name To enGene Therapeutics Effective April 8
Name change reflects transition towards potential commercial organization in 2027Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026enGene Therapeutics Inc. (formerly, enGene Holdings Inc.)
04-07 20:11
Electronic Arts misses preliminary Q3 revenue expectations
Electronic Arts misses preliminary Q3 revenue expectations Overview Gaming publisher's preliminary Q3 revenue missed analysts' expectations Net bookings for Q3 rose 38% yr/yr, driven by Battlefield 6 launch Outlook Company did not provide specific guidance due to pending acquisition Result Drivers B
02-04 05:17
BRIEF-KindlyMD Strengthens Leadership Team With Senior Finance Talent
Dec 8 (Reuters) - Kindly MD Inc NAKA.O: KINDLYMD STRENGTHENS LEADERSHIP TEAM WITH SENIOR FINANCE TALENT KINDLY MD INC - TERI GENDRON APPOINTED AS CFO AND TREASURER Source text: ID:nBw9b6hx2a Further c...
2025-12-08 21:07
BRIEF-Legend Biotech Highlights New Carvykti® Data In Multiple Myeloma And First-In-Human Results From Novel Car-T Platform In Non-Hodgkin Lymphoma At Ash 2025
Dec 6 (Reuters) - Legend Biotech Corp LEGN.O: LEGEND BIOTECH HIGHLIGHTS NEW CARVYKTI® DATA IN MULTIPLE MYELOMA AND FIRST-IN-HUMAN RESULTS FROM NOVEL CAR-T PLATFORM IN NON-HODGKIN LYMPHOMA AT ASH 2025 ...
2025-12-07 03:02
